Viraj Degaonkar - Concepedia

Concepedia

Author

Viraj Degaonkar

Queen Mary University of London

Also Known As

V. Degaonkar, Viraj Degaonkar

20

Publications

1.4K

Citations

12

H-Index

19

Concepts

All Affiliations

Queen Mary University of London University of Tsukuba Fred Hutch Cancer Center Klinikum rechts der Isar Northwestern University

VD

About

Viraj Degaonkar is an author at Queen Mary University of London specializing in urology, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	654
2	Immunology	3	3	85
3	Surgical Oncology	3	3	88
4	Health Sciences	2	2	26
5	Pathology	2	2	37

Viraj Degaonkar

×

13

Publications

1.4K

Citations

12

H-Index

	Year	Citations
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Nature Adjuvant ImmunotherapyCancer ImmunosurveillanceUrologyGenitourinary Cancer	2021	578
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, The Lancet Oncology UrologyVersus ObservationGenitourinary CancerMedicineMuscle-invasive Urothelial Carcinoma	2021	393
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, European Urology UrologyOverall SurvivalGenitourinary CancerImvigor010 TrialMedicine	2023	112
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma Alexandra Drakaki, Preet K. Dhillon, Heather A. Wakelee, OncoImmunology	2020	59
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). Maha Hussain, Thomas Powles, Peter Albers, Journal of Clinical Oncology Surgical OncologyImmunologyImmunotherapeuticsImmunotherapyPrimary Resection	2020	51
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Thomas Powles, Ariel Galapo Kann, Daniel Castellano, New England Journal of Medicine	2025	32
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade Habib Hamidi, Yasin Şenbabaoğlu, Niha Beig, Cancer Cell Molecular HeterogeneityUrologyGenitourinary CancerPd-l1 BlockadeUrothelial Carcinoma	2024	27
1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Annals of Oncology Surgical OncologyUrologyGenitourinary CancerMedicinePathology	2020	24
Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice Alexandra Drakaki, Patricia Luhn, Heather A. Wakelee, Annals of Oncology Systemic CorticosteroidsUrologyCancer ImmunosurveillanceMedicineImmunology	2019	21
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma Alexandra Drakaki, Allan J. Pantuck, Shivani K. Mhatre, Urologic Oncology Seminars and Original Investigations	2020	21

Page 1